Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Br J Haematol ; 201(1): 75-85, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36480431

RESUMEN

The increased expression of programmed death-ligands 1 and 2 (PD-L1 and PD-L2, respectively) on tumour cells contributes to immune evasion, suggesting that these proteins are attractive therapeutic targets. This study aimed to evaluate the validity of cerebrospinal fluid (CSF) soluble PD-L1 (sPD-L1) and soluble PD-L2 (sPD-L2) as biomarkers for primary central nervous system lymphoma (PCNSL). We determined the CSF concentrations of sPD-L1 and sPD-L2 in 46 patients with PCNSL using enzyme-linked immunosorbent assays (ELISAs). A control group comprised 153 patients with other brain tumours, inflammatory/infectious status, or neurodegenerative diseases. Only CSF sPD-L1 levels were significantly higher in patients with PCNSL relative to the controls. CSF sPD-L1 also exhibited superior overall discrimination performance compared to CSF sPD-L2 in diagnosing PCNSL. Compared with patients with PCNSL with low CSF sPD-L1 levels, more patients with high levels had high serum lactate dehydrogenase levels, leptomeningeal involvement, and deep-brain involvement. Furthermore, CSF sPD-L1 could predict poor survival in PCNSL but CSF sPD-L2 could not. Intriguingly, CSF sPD-L1 levels were correlated with disease status and their dynamic changes post treatment could predict time to relapse. In conclusion, this study identified CSF sPD-L1 as a promising prognostic biomarker, indicating a therapeutic potential of PD-L1 blockade in PCNSL.


Asunto(s)
Antígeno B7-H1 , Linfoma , Humanos , Antígeno B7-H1/metabolismo , Pronóstico , Sistema Nervioso Central , Linfoma/diagnóstico
2.
Hematology ; 29(1): 2365096, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38958506

RESUMEN

BACKGROUND/PURPOSE: The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan. METHODS: This retrospective, chart review-based, non-interventional study collected data on RRMM patients (≥20 years old) receiving pomalidomide-based treatment between January 2017 and December 2020 across five sites in Taiwan. RESULTS: Median age of the study population was 65.6 years. Approximately 75% patients received a doublet regimen and 25% were on a triplet regimen. Disease progression was the most common cause for switching to pomalidomide-based treatments in doublet (71.2%) and triplet (58.3%) groups. Patients in doublet and triplet groups (>80%) received 4 mg pomalidomide as a starting dose. Overall response rate (ORR: 31.5% and 45.8%) and median progression-free survival (PFS: 4.7 and 6.8 months) were reported in the doublet and triplet regimen. Doublet regimen was discontinued mainly due to disease progression or death (78.1%); however, triplet regimen patients mainly terminated their treatment due to reimbursement limitations (29.2%). Healthcare resource utilization (HRU) was comparable between doublet and triplet groups. CONCLUSION: In Taiwan, half of RRMM patients received pomalidomide-based triplet regimens. Triplet regimens showed a trend towards better outcomes with longer PFS and higher response rates compared to doublets. Notably, the duration of triplet use is influenced by reimbursement limitations. This study provides insight into RRMM treatment patterns in Taiwan and the findings suggest that triplet regimens may be a better alternative than doublet regimens.


Asunto(s)
Mieloma Múltiple , Talidomida , Humanos , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/mortalidad , Talidomida/análogos & derivados , Talidomida/uso terapéutico , Talidomida/administración & dosificación , Anciano , Femenino , Masculino , Taiwán , Estudios Retrospectivos , Persona de Mediana Edad , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Anciano de 80 o más Años , Adulto , Recurrencia
3.
Front Oncol ; 11: 695410, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34123862

RESUMEN

BACKGROUND: The therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone alone. However, the real-world effectiveness of Pom/Dex in these patients in Taiwan remains unclear. METHODS: This multicenter, registry-based study retrospectively reviewed the medical records of 49 consecutive patients undergoing Pom/Dex treatment for RRMM. We investigated the overall response rate (ORR) and PFS in these patients. The patients were stratified into two groups: those who received two (n=33) and those who received more than two (n=16) prior lines of treatment according to the numbers of regimens before Pom/Dex therapy. The differences in ORR and PFS between these two groups were further analyzed. We also analyzed factors attributed to disease progression. RESULTS: The ORR was 47.7%, and the median PFS was 4.0 months (range, 0.1-21.1). Patients who received two prior lines of treatment had a higher ORR than those who received more than two prior lines of treatment (55.2% vs. 33.3%; p=0.045). The median PFS of these groups was 4.8 and 3.9 months, respectively (p=0.805). Primary lenalidomide refractoriness reduced the risk of myeloma progression following Pom/Dex treatment (hazard ratio, 0.14; p=0.001). CONCLUSIONS: The median PFS following Pom/Dex treatment in Taiwanese RRMM patients in a real-world setting was similar to that reported by the MM-003 trial. Primary lenalidomide refractoriness should not be an obstacle for Pom/Dex treatment in RRMM.

4.
J Biomed Mater Res A ; 87(1): 165-75, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18085650

RESUMEN

The surface of superparamagnetic iron oxide nanoparticles (SPIO) with different molecular weight of poly(ethylene glycol) (PEG) and folic acid (FA) were synthesized. The SPIO-PEG-FA nanoparticles are well-dispersed and have good stability in various pH solutions. The lack of hysterestis and remanence at ambient temperatures is characteristic of superparamagnetic materials for SPIO-PEG-FA. The uptake by macrophage for SPIO-PEG-FA is lower than that of Feridex I.V. even at higher concentration. Internalization of SPIO-PEG-FA in targeted cells (KB cells) was observed by flow-cytometric analysis and in vitro MR imaging. The intensity change of positive KB cell tumor (-20 to 25%) is significantly lower than that of negative HT-1080 cell tumor from precontrast to postcontrast images of the tumor by in vivo MR imaging. These preliminary results demonstrated that SPIO-PEG-FA have the ability to target folate receptor.


Asunto(s)
Proteínas Portadoras/química , Ácido Fólico/química , Imagen por Resonancia Magnética , Nanopartículas/química , Polietilenglicoles/química , Receptores de Superficie Celular/química , Animales , Medios de Contraste/química , Compuestos Férricos/química , Citometría de Flujo , Receptores de Folato Anclados a GPI , Humanos , Células KB , Macrófagos/metabolismo , Ratones , Ratones SCID , Microscopía Electrónica de Transmisión , Nanopartículas/ultraestructura , Espectroscopía Infrarroja por Transformada de Fourier , Termogravimetría , Ensayos Antitumor por Modelo de Xenoinjerto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA